[{"id":"57288cee-f3b1-4cec-ae85-3fdf330023c7","acronym":"PBC039","url":"https://clinicaltrials.gov/study/NCT05396300","created_at":"2024-04-30T20:56:25.696Z","updated_at":"2025-02-25T13:41:03.634Z","phase":"Phase 1","brief_title":"A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05396300 - PBC039","lead_sponsor":"Weijia Fang, MD","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • C-13-60"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"8100f49e-ecbc-41b2-9130-5ed625da8fc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669496","created_at":"2025-02-25T13:40:17.235Z","updated_at":"2025-02-25T13:40:17.235Z","phase":"Phase 2/3","brief_title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors","source_id_and_acronym":"NCT04669496","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI • CEACAM5 • MUC16","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI • CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"5d2c2920-4c31-4b00-92b5-849908e509b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00819208","created_at":"2021-01-18T03:06:46.778Z","updated_at":"2025-02-25T14:06:40.996Z","phase":"","brief_title":"Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer","source_id_and_acronym":"NCT00819208","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 889","initiation":"Initiation: 06/02/2009","start_date":" 06/02/2009","primary_txt":" Primary completion: 12/15/2029","primary_completion_date":" 12/15/2029","study_txt":" Completion: 12/15/2030","study_completion_date":" 12/15/2030","last_update_posted":"2025-02-17"},{"id":"1214d7da-84ed-4b32-b0d2-16d88418f5bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06821048","created_at":"2025-02-25T15:46:38.357Z","updated_at":"2025-02-25T15:46:38.357Z","phase":"Phase 1","brief_title":"Study of CEA Targeting CAR-T in the Treatment of CEA-Positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT06821048","lead_sponsor":"Weijia Fang, MD","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/24/2024","start_date":" 07/24/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-11"},{"id":"80fa2f9c-498f-458f-b650-2771cce8af16","acronym":"","url":"https://clinicaltrials.gov/study/NCT05952453","created_at":"2023-07-20T14:08:52.311Z","updated_at":"2025-02-25T15:28:12.738Z","phase":"Phase 2","brief_title":"Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro","source_id_and_acronym":"NCT05952453","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" CEACAM5 • MUC16","pipe":"","alterations":" ","tags":["CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 10/30/2028","primary_completion_date":" 10/30/2028","study_txt":" Completion: 12/30/2030","study_completion_date":" 12/30/2030","last_update_posted":"2025-02-10"},{"id":"d4706b4b-87ff-43ad-a128-bb849b25cb0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01972919","created_at":"2021-01-18T08:58:44.421Z","updated_at":"2025-02-25T15:32:57.905Z","phase":"Phase 2","brief_title":"MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT01972919","lead_sponsor":"Medical College of Wisconsin","biomarkers":" CEACAM5","pipe":" | ","alterations":" SMAD4 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMAD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/10/2015","start_date":" 12/10/2015","primary_txt":" Primary completion: 12/13/2023","primary_completion_date":" 12/13/2023","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-10"},{"id":"8ba4b2c4-2d3e-460e-9a2f-77116f701fa8","acronym":"S1513","url":"https://clinicaltrials.gov/study/NCT02890355","created_at":"2021-01-18T14:11:10.280Z","updated_at":"2025-02-25T16:36:47.130Z","phase":"Phase 2","brief_title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02890355 - S1513","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CEACAM5","pipe":" | ","alterations":" HRD","tags":["BRCA1 • BRCA2 • HRD • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-06"},{"id":"21e02173-6a70-45fc-8771-2545b671be82","acronym":"NCI-2018-01071","url":"https://clinicaltrials.gov/study/NCT03263650","created_at":"2021-01-18T16:07:22.101Z","updated_at":"2025-02-25T14:58:18.982Z","phase":"Phase 2","brief_title":"Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men with AVPC","source_id_and_acronym":"NCT03263650 - NCI-2018-01071","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • PTEN • RB1 • CEACAM5","pipe":"","alterations":" ","tags":["TP53 • PTEN • RB1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • prednisone • cabazitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 10/03/2017","start_date":" 10/03/2017","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-05"},{"id":"9366e737-3f01-4636-8df7-72a9b9c74478","acronym":"CF102-222PC","url":"https://clinicaltrials.gov/study/NCT06387342","created_at":"2024-04-29T15:45:20.577Z","updated_at":"2025-02-25T12:39:00.064Z","phase":"Phase 2","brief_title":"Namodenoson Treatment of Advanced Pancreatic Cancer","source_id_and_acronym":"NCT06387342 - CF102-222PC","lead_sponsor":"Can-Fite BioPharma","biomarkers":" CEACAM5 • CA 19-9","pipe":"","alterations":" ","tags":["CEACAM5 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e namodenoson (CF102)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/10/2024","start_date":" 11/10/2024","primary_txt":" Primary completion: 07/15/2026","primary_completion_date":" 07/15/2026","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2025-01-31"},{"id":"d131c943-6eec-4c31-8917-631846af0eef","acronym":"","url":"https://clinicaltrials.gov/study/NCT06090994","created_at":"2025-02-27T18:34:32.567Z","updated_at":"2025-02-27T18:34:32.567Z","phase":"Phase 4","brief_title":"Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy","source_id_and_acronym":"NCT06090994","lead_sponsor":"Fudan University","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 756","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-08-20"},{"id":"729dd6a2-45ba-450d-b222-251f402464f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06461338","created_at":"2025-02-26T14:13:55.381Z","updated_at":"2025-02-26T14:13:55.381Z","phase":"","brief_title":"Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study","source_id_and_acronym":"NCT06461338","lead_sponsor":"Guangzhou University of Traditional Chinese Medicine","biomarkers":" CEACAM5 • KRT19","pipe":"","alterations":" ","tags":["CEACAM5 • KRT19"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-08-15"},{"id":"53ffeb2e-2025-434c-8ac8-ee1e44968dd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05325281","created_at":"2022-04-16T16:18:13.640Z","updated_at":"2025-02-25T16:32:58.264Z","phase":"Phase 1","brief_title":"CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT05325281","lead_sponsor":"Medical College of Wisconsin","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Bylantra (devimistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-07-29"},{"id":"15be3123-0c37-4344-af6c-5d926b24472c","acronym":"ISMCC","url":"https://clinicaltrials.gov/study/NCT06509880","created_at":"2025-02-27T07:49:54.556Z","updated_at":"2025-02-27T07:49:54.556Z","phase":"Phase 1/2","brief_title":"Immunosurveillance for Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06509880 - ISMCC","lead_sponsor":"MIPO Clinic","biomarkers":" CD8 • CEACAM5 • CD4","pipe":"","alterations":" ","tags":["CD8 • CEACAM5 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/15/2024","start_date":" 07/15/2024","primary_txt":" Primary completion: 07/25/2024","primary_completion_date":" 07/25/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-07-19"},{"id":"a0cf279a-8d5c-46c3-9bca-6f57de2820c1","acronym":"NAUTICALCRC","url":"https://clinicaltrials.gov/study/NCT05004350","created_at":"2021-08-13T12:53:27.664Z","updated_at":"2025-02-25T16:16:36.860Z","phase":"Phase 2","brief_title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT05004350 - NAUTICALCRC","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type","tags":["BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/19/2023","primary_completion_date":" 12/19/2023","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-06-18"},{"id":"847c8261-9d7c-4c47-a268-27585ac7ebd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02600949","created_at":"2021-01-18T12:37:39.802Z","updated_at":"2024-07-02T16:34:26.760Z","phase":"Phase 1","brief_title":"Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer","source_id_and_acronym":"NCT02600949","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/11/2016","start_date":" 05/11/2016","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-06-12"},{"id":"86efa887-cf79-4781-8df5-578fd8d6c9b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03704662","created_at":"2021-01-18T18:09:12.683Z","updated_at":"2024-07-02T16:34:27.473Z","phase":"","brief_title":"Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03704662","lead_sponsor":"Medical College of Wisconsin","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 10/22/2018","start_date":" 10/22/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-11"},{"id":"b733a5ee-f14d-459f-a343-1204a150af38","acronym":"PEAPOD_FOS","url":"https://clinicaltrials.gov/study/NCT05563558","created_at":"2022-10-03T15:56:36.500Z","updated_at":"2024-07-02T16:34:27.128Z","phase":"Phase 2","brief_title":"Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)","source_id_and_acronym":"NCT05563558 - PEAPOD_FOS","lead_sponsor":"Fundacion Oncosur","biomarkers":" TP53 • PTEN • CEACAM5","pipe":"","alterations":" ","tags":["TP53 • PTEN • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • cabazitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/05/2023","start_date":" 05/05/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-06-11"},{"id":"5d9e3655-cb50-477b-86ac-5e2e42b0f19d","acronym":"BP42675","url":"https://clinicaltrials.gov/study/NCT04826003","created_at":"2021-04-01T16:52:30.647Z","updated_at":"2024-07-02T16:34:37.780Z","phase":"Phase 1/2","brief_title":"Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment","source_id_and_acronym":"NCT04826003 - BP42675","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 overexpression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • RG7827 • cibisatamab (RG7802)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2024-06-06"},{"id":"ccfd455c-e774-4e0e-bb52-ee525cf236c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04592237","created_at":"2021-01-19T20:28:42.436Z","updated_at":"2024-07-02T16:34:58.883Z","phase":"Phase 2","brief_title":"Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04592237","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • TP53 • PTEN • RB1 • CEACAM5","pipe":" | ","alterations":" PTEN mutation","tags":["PD-L1 • TP53 • PTEN • RB1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Zejula (niraparib) • cabazitaxel • cetrelimab (JNJ-63723283)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/29/2020","start_date":" 12/29/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-04"},{"id":"43707759-e80d-422e-92b4-48c987e89ea1","acronym":"CARMEN-LC06","url":"https://clinicaltrials.gov/study/NCT05245071","created_at":"2022-02-17T18:22:23.864Z","updated_at":"2024-07-02T16:34:59.736Z","phase":"Phase 2","brief_title":"Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA","source_id_and_acronym":"NCT05245071 - CARMEN-LC06","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tusamitamab ravtansine (SAR408701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 03/06/2024","primary_completion_date":" 03/06/2024","study_txt":" Completion: 09/02/2024","study_completion_date":" 09/02/2024","last_update_posted":"2024-05-31"},{"id":"b72569e3-5b2c-4b6d-a8ef-d641494aa19c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04357587","created_at":"2021-01-18T21:04:15.436Z","updated_at":"2025-02-25T16:25:47.207Z","phase":"Phase 1","brief_title":"Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer","source_id_and_acronym":"NCT04357587","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" MSI • CEACAM5","pipe":"","alterations":" ","tags":["MSI • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 08/06/2020","start_date":" 08/06/2020","primary_txt":" Primary completion: 09/25/2023","primary_completion_date":" 09/25/2023","study_txt":" Completion: 09/25/2023","study_completion_date":" 09/25/2023","last_update_posted":"2024-05-29"},{"id":"4ddeafce-3b8e-4b29-b230-0788f469d7b7","acronym":"PRORECT","url":"https://clinicaltrials.gov/study/NCT04525989","created_at":"2024-03-05T21:32:32.859Z","updated_at":"2024-07-02T16:35:02.544Z","phase":"","brief_title":"Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT)","source_id_and_acronym":"NCT04525989 - PRORECT","lead_sponsor":"Alexander Valdman","biomarkers":" CEACAM5 • FOXP3","pipe":"","alterations":" ","tags":["CEACAM5 • FOXP3"],"overall_status":"Recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-05-20"},{"id":"5b00f557-ca8a-462f-b909-21c075ffc4c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06307548","created_at":"2024-03-13T14:35:24.989Z","updated_at":"2024-07-02T16:35:02.807Z","phase":"Phase 1/2","brief_title":"Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer","source_id_and_acronym":"NCT06307548","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-17"},{"id":"8124bd6b-d159-4e19-8e69-ca6cc82c95bb","acronym":"CARMEN-LC05","url":"https://clinicaltrials.gov/study/NCT04524689","created_at":"2021-01-18T21:40:16.688Z","updated_at":"2024-07-02T16:35:02.714Z","phase":"Phase 2","brief_title":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","source_id_and_acronym":"NCT04524689 - CARMEN-LC05","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":" | ","alterations":" PD-L1 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • tusamitamab ravtansine (SAR408701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 03/12/2024","primary_completion_date":" 03/12/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-17"}]